Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
82 studies found for:    "spinocerebellar ataxia type 1" OR "Spinocerebellar Ataxia"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 6
Intervention: Genetic: All Participants
2 Completed
Has Results 		Dalfampridine and Gait in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxias Type 1;   Spinocerebellar Ataxias Type 2;   Spinocerebellar Ataxias Type 3;   Spinocerebellar Ataxias Type 6
Interventions: Drug: Dalfampridine;   Drug: Placebo
3 Active, not recruiting Biomarkers in Autosomal Dominant Cerebellar Ataxia
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia, Autosomal Recessive 3;   Episodic Ataxia, Type 7
Intervention: Other: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
4 Completed Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
Condition: Spinocerebellar Ataxia Type I
Intervention: Drug: Lithium Carbonate
5 Unknown † RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7
Condition: Spinocerebellar Ataxias
Intervention:
6 Recruiting Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Device: Transcranial Magnetic Stimulation
7 Completed Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias
Condition: Spinocerebellar Ataxia
Intervention:
8 Completed Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
Conditions: Spinocerebellar Ataxia Type 3;   Machado Joseph Disease
Interventions: Drug: Lithium Carbonate;   Drug: Placebo
9 Recruiting Parkinsonism in Spinocerebellar Ataxia Type 6
Condition: Spinocerebellar Ataxia Type 6
Intervention:
10 Completed Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Biological: IVIG
11 Not yet recruiting An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
Condition: Spinocerebellar Ataxias
Intervention: Drug: Intravenous Immune Globulin (IVIG)
12 Completed Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
Condition: SPINOCEREBELLAR ATAXIA 2
Intervention: Drug: LITHIUM CARBONATE
13 Completed Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: varenicline;   Drug: placebo
14 Unknown † Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
Conditions: Spinocerebellar Ataxias;   Spastic Paraplegias
Intervention:
15 Completed Neuromuscular Electrical Stimulation on Median Nerve Facilitates Low Motor Cortex Excitability in Human With Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Device: Neuromuscular electrical stimulation
16 Withdrawn Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: Placebo;   Drug: Sodium Phenylbutyrate
17 Recruiting A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
18 Recruiting An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
19 Recruiting A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose;   Drug: Placebo
20 Recruiting A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years